Passage Bio, Inc.
PASG • NASDAQ
Passage Bio, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO William Chou, with a market cap of $20.5M.
CEOWilliam Chou
Next Earnings
Upcoming earnings announcement for Passage Bio, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$2.57
Earnings History
Past 12 earnings reports for Passage Bio, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | -$4.09Est: -$2.55 | -60.4% | - | — |  10-K |
| Nov 10, 2025 | Q3 2025 | -$2.44Est: -$2.84 | +14.1% | - | — | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$2.96Est: -$1.72 | -72.1% | - | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.25Est: -$0.22 | -13.6% | - | — | 10-Q |
| Mar 4, 2025 | Q4 2024 | -$0.20Est: -$0.24 | +16.7% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.31Est: -$0.23 | -34.8% | -Est: $3.3M | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.26Est: -$0.31 | +16.1% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.30Est: -$0.36 | +16.7% | - | — | 10-Q |
| Mar 4, 2024 | Q4 2023 | -$0.30Est: -$0.40 | +25.0% | - | — | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.49Est: -$0.46 | -6.5% | - | — | — |
| Aug 7, 2023 | Q2 2023 | -$0.44Est: -$0.48 | +8.3% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.63Est: -$0.49 | -28.6% | - | — | — |